• Lexaria Bioscience received an Australian patent grant, No. 2023302884, covering pharmaceutical compositions and methods for treating hypertension.
• The patent runs through April 25, 2043.
• The grant marks the company’s seventh issued patent in the same family, with prior grants in the U.S., Europe, and Japan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606230925ACCESSWRNAPR_____1180774) on June 23, 2026, and is solely responsible for the information contained therein.